Motilal Oswal Nifty MidSmall Healthcare Index Fund Regular-Growth
Mid CapEquity: Sectoral-PharmaVery High Risk
PaisaSmart rating★★★★★0
Why this rating
This index fund/ETF has a beta of nan%, and an expense ratio of 1.21%, giving it a 0.0 star rating, based on the principle that lower values of |1-beta| and expense ratio result in higher ratings.
Our score weighs long-term performance, risk and consistency — not just past returns.
Returns
As of 7 Oct 2026
1W
+0.09%
1M
-2.46%
3M
+0.79%
6M
+20.71%
9M
+12.36%
1Y
+15.15%
Since launch
+11.21%
Portfolio
As of 31 Aug 2026
Market-cap split
Mid cap67.57%Small cap32.43%
P/E
38.29
P/B
4.80
Style
Growth
Sector allocation
Healthcare100.31%
Holdings (31)
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Laurus Labs Ltd. | 11.23% | ₹5.7 Cr | 29,782 |
| Lupin Ltd. | 8.01% | ₹4.07 Cr | 18,589 |
| Aurobindo Pharma Ltd. | 7.16% | ₹3.64 Cr | 21,187 |
| Fortis Healthcare Ltd. | 7.12% | ₹3.62 Cr | 39,889 |
| Glenmark Pharmaceuticals Ltd. | 5.63% | ₹2.86 Cr | 11,525 |
| Alkem Laboratories Ltd. | 4.70% | ₹2.39 Cr | 4,479 |
| Biocon Ltd. | 4.43% | ₹2.25 Cr | 54,611 |
| Ipca Laboratories Ltd. | 4.13% | ₹2.1 Cr | 10,633 |
| Mankind Pharma Ltd. | 4.11% | ₹2.09 Cr | 8,637 |
| Gland Pharma Ltd. | 3.46% | ₹1.76 Cr | 6,099 |
Fund details
In brief
Return that corresponds to the returns of the Nifty MidSmall Healthcare Total Return Index, subject to tracking error. Long term capital growth.
Investment objective
The scheme seeks to provide returns that, before expenses, correspond to the total returns of the securities as represented by Nifty MidSmall Healthcare Total Return Index, subject to tracking error.
Exit load
Exit load of 1%, if redeemed within 15 days.
Fund type
Open-ended
Min lumpsum
₹500
Min withdrawal
₹500
Lock-in
None
SIP
Available
SWP
Available
STP
Available
Purchase cut-off
15:00